期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 8, 期 2, 页码 175-181出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.8.2.175
关键词
capromab pendetide; ProstaScint (R); prostate-specific membrane antigen; radioimmunoscintigraphy
类别
The provision of accurate prognostic information is a long-standing goal for effective management of prostate adenocarcinoma. Nontargeted imaging modalities are less efficient at detecting slow-growing prostate cancers. Prostate-specific membrane antigen has emerged as a superior biomarker, especially for the evaluation of metastatic spread. Advances in imaging technology have focused clinical interest on indium-111 capromab (In-111 capromab) pendetide, a radioimmunoconjugate that detects prostate-specific membrane antigen expression in vivo. Single-photon emission computed tomography capromab pendetide images, fused with those generated by computed tomography or magnetic resonance, have engendered improvements in localization accuracy by correlating high signal intensity with anatomic structures. In long-term outcomes studies, fused In-111 capromab pendetide scans have delivered
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据